The Shareholders Foundation announces that an investigation on behalf of investors of Puma Biotechnology Inc (NYSE:PBYI) shares was launched over potential securities laws violations by Puma Biotechnology Inc and certain of its directors and officers.
Investors who purchased shares of Puma Biotechnology Inc (NYSE:PBYI) have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
The investigation by a law firm focuses on whether certain statementsregarding Puma Biotechnology’s business, its prospects and its operations were materially false and misleading at the time they were made.
On July 22, 2014, Puma Biotechnology Inc announced positive top line results from the Phase III clinical trial of Puma’s investigational breast cancer drug, PB272 (neratinib). Puma Biotechnology Inc said that based on the results from the ExteNET study, Puma plans to file for regulatory approval of neratinib in the extended adjuvant setting in the first half of 2015. Shares of Puma Biotechnology Inc (NYSE:PBYI) jumped from $59.03 per share on July 22, 2014, to $233.43 per share on July 23, 2014 and continued to increase to as high as $275.07 per share in September 2014.
Then on December 2, 2014, Puma Biotechnology Inc announced that it intends to delay its proposed timeline for filing the new drug application (“NDA”) until the first quarter of 2016. Puma Biotechnology Inc said that it originally focused on the proposed clinical indication of HER2-positive metastatic breast cancer and now plans to apply first for extended adjuvant HER2-positive early stage breast cancer. Share of Puma Biotechnology Inc (NYSE:PBYI) declined from $228.82 per share on December 2, 2014, to $189.51 per share on December 3, 2014.
On March 3, 2015, NYSE:PBYI shares closed at $206.01 per share
Those who purchased shares of Puma Biotechnology Inc (NYSE:PBYI) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego